Education
About Us
Working with TipRanks
Follow Us
Creo Medical Group PLC (GB:CREO)
LSE:CREO
CREO Stock Chart & Stats
10.15p
-0.13p(-0.63%)
At close: 4:00 PM EST
10.15p
-0.13p(-0.63%)
Day’s Range― - ―
52-Week Range9.22p - 18.50p
Previous CloseN/A
Volume60.81K
Average Volume (3M)975.48K
Market Cap
£68.57M
Enterprise Value51.76M
Total Cash (Recent Filing)£20.50M
Total Debt (Recent Filing)£4.20M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
May 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding412,473,330
10 Day Avg. Volume668,834
30 Day Avg. Volume975,484
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)1.66
Price to Sales (P/S)17.63
P/FCF Ratio-3.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueCreo's business model includes recurring consumable sales tied to each procedure. This creates a durable, predictable revenue stream once clinical adoption is established, improving lifetime customer value and smoothing unit-sales volatility over the medium term.
Operational Restructuring And Strategic Stake SaleA 24% cost reduction plus the 51% CME stake sale to Micro‑Tech represents a structural change: lower fixed costs and strategic partnership can supply resources, distribution or capital. Combined with higher continuing-operation revenue, this materially improves operational resilience.
Improving Leverage And Equity CoverageSlightly reduced debt and equity covering a large portion of assets reduce solvency risk and provide a balance-sheet buffer. This improves financial flexibility long-term, lowering refinancing pressure and enabling more sustainable funding of R&D and commercialization.
Bears Say
Severe Revenue DeclineA collapse in revenue indicates material loss of commercial traction or discontinued operations, shrinking scale and limiting the firm's ability to achieve operating leverage. This structural shrinkage raises the likelihood of further capital raises and constrains long‑term market positioning.
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flows show the company is burning cash to fund operations. Over months this reduces runway, curtails investment in sales and R&D, increases refinancing risk, and may necessitate dilutive financing or asset sales to sustain operations.
Sustained Net Losses And Margin DeteriorationLarge net losses and worsening margins indicate persistent unprofitability and cost structure issues. This undermines ability to self‑fund growth, erodes equity, and suggests structural challenges in pricing, unit economics or scale that must be addressed for long‑term viability.
Creo Medical News
CREO FAQ
What was Creo Medical Group PLC’s price range in the past 12 months?
Creo Medical Group PLC lowest share price was 9.22p and its highest was 18.50p in the past 12 months.
What is Creo Medical Group PLC’s market cap?
Creo Medical Group PLC’s market cap is £68.57M.
When is Creo Medical Group PLC’s upcoming earnings report date?
Creo Medical Group PLC’s upcoming earnings report date is May 25, 2026 which is in 91 days.
How were Creo Medical Group PLC’s earnings last quarter?
Creo Medical Group PLC released its earnings results on Sep 22, 2025. The company reported 0p earnings per share for the quarter, the consensus estimate of N/A by 0p.
Is Creo Medical Group PLC overvalued?
According to Wall Street analysts Creo Medical Group PLC’s price is currently Overvalued.
Does Creo Medical Group PLC pay dividends?
Creo Medical Group PLC does not currently pay dividends.
What is Creo Medical Group PLC’s EPS estimate?
Creo Medical Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Creo Medical Group PLC have?
Creo Medical Group PLC has 412,473,330 shares outstanding.
What happened to Creo Medical Group PLC’s price movement after its last earnings report?
Creo Medical Group PLC reported an EPS of 0p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -2.228%.
Which hedge fund is a major shareholder of Creo Medical Group PLC?
Currently, no hedge funds are holding shares in GB:CREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Creo Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.72%
Trailing 12-Months
Company Description
Creo Medical Group PLC
Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
Technical Analysis
Options Prices
Currently, No data available
---